Securing the Future of the U.S. Biopharmaceutical Industry: The Most-Favored-Nation Paradox
February 5, 2026
By Sujai Shivakumar and Anne Pritchett The Trump administration is pursuing lowering prescription drug costs primarily to end what it describes as “global freeloading” and to ensure U.S. patients pay prices comparable to those in other developed nations. The administration argues that while the United States represents less than 5 percent